Arcturus says ARCT-810 Phase 2 interim data in OTC deficiency show safety, biomarker improvement
Bitget2026/09/23 20:01- Arcturus reported interim Phase 2 data showing ARCT-810 was generally safe, with fasting ammonia maintained in-range and glutamine reduced.
- LUNAR 2.0 delivery platform showed about 40-fold higher protein expression versus LUNAR 1.0 in non-human primates.
- Separate primate study showed LUNAR 2.0 delivered 38-fold higher hOTC expression potency than ARCT-810’s key lipid ATX-95.
- FDA feedback supports adding ARCT-2601, a LUNAR 2.0-based OTCD candidate, into the ongoing Phase 2 study near year-end for ages 12+.
- ARCT-2601 is expected to enable lower or less frequent dosing versus ARCT-810, based on non-human primate data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
